ovarian-cancer

Documents about ovarian-cancer

• APG-2449 in Patients With Advanced Solid Tumors#867548ClinicalTrials.gov
• Phase I Study of OSI-930 and Erlotinib in Cancer Tumors#909544ClinicalTrials.gov
• Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation#806322ClinicalTrials.gov
• Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer#834388ClinicalTrials.gov
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers#411394ClinicalTrials.gov
• Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy#829447ClinicalTrials.gov
• Liquid Biopsy Evaluation and Repository Development at Princess Margaret#849285ClinicalTrials.gov
• P-MAPA activates TLR2 and TLR4 signaling while its combination with IL-12 stimulates CD4+ and CD8+ effector T cells in ovarian cancer#255720Repositório Institucional Unesp
• Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial)#800566ClinicalTrials.gov
• Is platinum the new gold? Re-evaluating platinum's enduring role and future potential in the era of novel ovarian cancer therapies#922955HAL (France)
• Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting#124547HAL (France)
• Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer#261503ClinicalTrials.gov
• Ovarian carcinoma in patients aged ≥80 years: A retrospective multicenter study of management and survival in the FRANCOGYN population#350699HAL (France)
• Data and materials of" <b>Dual </b><b>inhibition</b><b> of CDK12 and PARP disrupts a tumor-fibroblast feedback loop to suppress proliferation in HRP ovarian cancer </b>"#478444Figshare
• Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium#675890eScholarship
• Effectiveness of Care in Certified Cancer Centres in Germany#806143ClinicalTrials.gov
• Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention#869816ClinicalTrials.gov
• Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients#901680ClinicalTrials.gov
• Multi-Omic Profiling Reveals Antibody-Drug Conjugate Targetability in Ovarian Cancer#133222bioRxiv / medRxiv
• Psychological flexibility, distress, and coping in ovarian cancer survivors.#214225NCBI PubMed Central
• Exosomes in Ovarian Cancer: Promoters, Biomarkers, and Therapeutic Targets.#298884NCBI PubMed Central
• DNA methylation biomarkers for early detection of ovarian cancer.#785588NCBI PubMed Central
• A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)#829371ClinicalTrials.gov
• Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients#67808ClinicalTrials.gov
• PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis#842522ClinicalTrials.gov
• Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer?#801093ClinicalTrials.gov
• The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression#830061ClinicalTrials.gov
• Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer#869052ClinicalTrials.gov
• Phase II ABT-888 With Cyclophosphamide#801943ClinicalTrials.gov
• Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients#810128ClinicalTrials.gov
• Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer#230469ClinicalTrials.gov
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy#881753ClinicalTrials.gov
• A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）#890396ClinicalTrials.gov
• Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial#811593ClinicalTrials.gov
• Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer#18621ClinicalTrials.gov
• Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study#902267ClinicalTrials.gov
• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer#803462ClinicalTrials.gov
• Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars#910507ClinicalTrials.gov
• Ovarian cancer staging and follow-up: updated guidelines from the European Society of Urogenital Radiology female pelvic imaging working group#274180HAL (France)
• Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy#851520ClinicalTrials.gov
• A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor#916902ClinicalTrials.gov
• A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers#833788ClinicalTrials.gov
• Validation of a Mouse Model of Pancreatic Carcinogenesis#835173ClinicalTrials.gov
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer#889350ClinicalTrials.gov
• Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors#812342ClinicalTrials.gov
• Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC)#162484ClinicalTrials.gov
• Rethinking depression diagnosis in ovarian cancer: The role of somatic symptoms.#174432NCBI PubMed Central
• Ferroptosis Signature Correlates with Ovarian Cancer Prognosis and Chemotherapy Response.#368045NCBI PubMed Central
• CTPS1 is an unexplored vulnerability in breast and ovarian cancer.#433979NCBI PubMed Central
• The Development of Human Immunologic Assays Specific to Folate Receptor Antigen#683074ClinicalTrials.gov